Its top-selling treatment, Keytruda, will lose patent protection in a few years ... and where it doesn't already have them, ...

In the last year, many Merck & Co., Inc. (NYSE ... their decisions solely on what the directors of a company have been doing, we do think it is perfectly logical to keep tabs on what insiders ...

With many of the Magnificent 7 stocks reporting earnings the week of October 28, investors’ attention was on technology ...

We are raising our fair value estimate for Waters to $340 per share, from $323 previously, based on cash flows generated since our last valuation update. Our valuation is based on discounted cash ...

Narrow-moat Daiichi Sankyo is a Japanese drugmaker with a global footprint and cutting-edge development platform for antibody drug conjugates. As an established pharmaceutical company with a long ...

However, analysts have noted some concerns regarding ... their benefits to healthcare providers and patients. What risks does Merck face from potential patent expirations? Merck, like many ...

At times, the cycling patent news cycle feels intense and a little relentless. A patent for exciting new components or some ...

In this article, we are going to take a look at where Merck & Co ... pointed out that many investors are hesitant, particularly those in their mid-30s and younger, who have not experienced ...

The Drug Price Competition and Patent Term Restoration Act of 1984, better known as the Hatch-Waxman Act, is responsible for ...